Results 201 to 210 of about 64,314 (239)
Some of the next articles are maybe not open access.

Etanercept

BioDrugs, 2004
Etanercept is a dimeric fusion protein based on the p75 tumor necrosis factor (TNF) receptor. It binds to TNFalpha and blocks its biological activity. Subcutaneous etanercept is effective in the treatment of rheumatoid arthritis, psoriatic arthritis, and polyarticular-course juvenile rheumatoid arthritis. More recently, etanercept has shown efficacy in
Paul L, McCormack, Keri, Wellington
openaire   +2 more sources

Re-challenge with Etanercept in patients with Etanercept-induced Neutropenia

Clinical Rheumatology, 2011
TNF blockers have rarely been associated with haematological complications; however, there are scattered case reports of marked neutropenia with their use and necessitating in their withdrawal. We would like to report a series of five patients who developed neutropenia with etanercept use; however, all these patients were re-challenged with etanercept ...
Haroon, Muhammad   +2 more
openaire   +3 more sources

Etanercept in psoriasis

Expert Opinion on Pharmacotherapy, 2004
Psoriasis is a chronic skin disorder that affects approximately 2% of the US and European populations. Several lines of evidence have demonstrated the correlation between elevated levels of TNF and psoriasis, suggesting that interfering with the inflammatory effects of TNF may help resolve psoriatic lesions. The biological agent, etanercept, is a fully
openaire   +2 more sources

Etanercept

DMW - Deutsche Medizinische Wochenschrift, 2003
U, Mühlhäuser   +2 more
openaire   +3 more sources

Etanercept

Reactions Weekly, 2022
openaire   +1 more source

Etanercept

Reactions Weekly, 2009
  +4 more sources

Home - About - Disclaimer - Privacy